7. Natera Inc. (NASDAQ:NTRA)
Number of Hedge Fund Holders — 77
Cancer Monitoring Growth Gives Diagnostics Investors More to Examine
Natera, Inc. (NASDAQ: NTRA) offers exposure to oncology through testing rather than drug development, with recent financial results showing how quickly that business is expanding. Second-quarter revenue increased 37.7% to $752.8 million, while oncology test volume rose 57.2% to approximately 296,700 tests. Across its broader portfolio, the company processed more than one million tests during the quarter. Its cancer testing opportunity centers on molecular residual disease, or MRD, using circulating tumor DNA to help assess whether disease remains after treatment or may be returning. That positions the business around repeated clinical decisions rather than a single prescription event.
The clinical evidence base continued expanding in October. The company announced 20 abstracts featuring its technology at the European Society for Medical Oncology congress, including research involving its latest Signatera Genome platform. Its subsequent October 27 update highlighted findings across bladder cancer and other solid tumors, reinforcing efforts to establish where MRD-guided treatment decisions may be useful. Chief Executive Officer Steve Chapman had earlier pointed to “record growth in oncology volumes.” For investors, the important distinction is between demonstrating that a test detects a signal and establishing how the information should influence patient care. Broader evidence can support adoption, but different indications require their own clinical justification.
Financial progress is visible, although sustained profitability remains a separate milestone. The second-quarter net loss narrowed to $67 million from $100.9 million a year earlier, while reported gross margin increased to 64.5%. Revenue also included a $52.3 million change in estimates for prior revenue accruals, a detail investors should consider when assessing the underlying growth rate. For those comparing cancer diagnostics stocks, the opportunity lies in expanding clinical use, reimbursement, and operating efficiency. More tests can strengthen the business, but the most valuable growth is the kind that eventually leaves more cash after the laboratory, research, and commercial bills have been paid.
Ranking rationale — Natera, Inc. (NASDAQ: NTRA) ranks seventh with 77 hedge fund holders. Rapid oncology testing growth and an expanding clinical evidence base support its position, while reimbursement, revenue-estimate adjustments, spending, and the path to sustained profitability require continued attention.
